Skip to content
Peptigraph home

IGF-1 LR3 Benefits: Claims vs What Studies Show

Benefits people claim for IGF-1 LR3, set against what published studies measured, and where no study exists.

Medical review pendingIGF-1 analogUpdated
Strongest evidence
Human observational
Human / animal studies
1 / 10
in our evidence file (PubMed search, 11 Oct 2026)
FDA status
Not approved
research chemical

Claimed benefits and what studies show

Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

IGF-1 LR3 claimed benefits and the studies behind them
ClaimBest evidenceStudies (human / animal)What was measuredPage
BodybuildingHuman observational evidence, 3 of 41 / 0Black-market product composition; Regulatory status and evidence for physique claimsEvidence for bodybuilding
Muscle growthReview only0 / 7Regulatory status and evidence for physique claims; Fetal growth; Body composition and cognitionEvidence for muscle growth
Growth hormoneAnimal evidence, 2 of 40 / 2Insulin secretion; Growth performance; Endogenous GHEvidence for growth hormone

Strongest study per claim: Bodybuilding, Growth hormone & IGF research 2010, PMID 20675162; Muscle growth, Frontiers in endocrinology 2026, PMID 42395176; Growth hormone, Journal of developmental origins of health and disease 2023, PMID 37114757.

What the studies measured

IGF-1 LR3 outcomes in published studies
OutcomeResultStudy typeSource
Black-market product compositionA black-market injection vial contained a His-tagged IGF-I variant; its effects in humans are not described.Human case reportGrowth hormone & IGF research 2010, PMID 20675162
Regulatory status and evidence for physique claimsThe review notes no regulatory approval for physique- or performance-related indications of these peptides, including the long-acting IGF analogue.ReviewFrontiers in endocrinology 2026, PMID 42395176
Fetal growthOne week of IGF-1 LR3 did not improve growth in growth-restricted fetal sheep.Animal · sheep (not a human result)n = 14American journal of physiology. Endocrinology and metabolism 2025, PMID 39679943
Body composition and cognitionIntranasal LR3-IGF-1 improved body composition (not specified in the abstract) in male 5XFAD mice but did not significantly change cognition.Animal · mouse (not a human result)Journal of Alzheimer's disease 2025, PMID 39610283
Insulin secretionFetal plasma insulin fell with infusion, and insulin during the hyperglycemic clamp was 66% lower than control.Animal · sheep (not a human result)n = 10Journal of developmental origins of health and disease 2023, PMID 37114757
Daily weight gainIn the second 9 days, LR3IGF-I-infused neonatal pigs gained 457 g/d versus 386 g/d for controls.Animal · pig (not a human result)The British journal of nutrition 2002, PMID 12067429
Clearance from wound fluidHalf-life in wound fluid was 563 min for LR3-IGF-I versus 872 min for IGF-I, 861 for IGF-II and 324 for insulin.Animal · rat (not a human result)The American journal of physiology 1999, PMID 10198302
Growth performanceA four-day infusion of 180 micrograms/kg/day LR3IGF-I decreased average daily gain, food intake and plasma IGFBP-3, IGF-I and insulin in pigs.Animal · pig (not a human result)The Journal of endocrinology 1997, PMID 9488001
Endogenous GHMean plasma GH fell by 23% and the area under the GH peaks by 60%.Animal · pig (not a human result)The Journal of endocrinology 1997, PMID 9488001
Overall growthFractional weights of adrenals, gut, kidneys and spleen increased with LR3IGF-I, but overall growth was not stimulated.Animal · guinea pig (not a human result)The Journal of endocrinology 1995, PMID 7561636
Body and gut weightLR3IGF-I (not IGF-I) increased body weight and wet weight of small and large intestine by 20% versus controls; muscle was not measured.Animal · rat (not a human result)Gut 1995, PMID 8549937
Carcass proteinLR3-IGF-I had no positive effect on carcass protein accretion in tumour-bearing rats.Animal · rat (not a human result)The Biochemical journal 1994, PMID 8053901
Growth in diabetic ratsThe IGF-I variants were 2.5-3 times more potent than IGF-I at restoring growth in diabetic rats.Animal · rat (not a human result)The Biochemical journal 1993, PMID 7683875
Muscle protein synthesisAll IGF peptides raised muscle protein-synthesis rates and RNA levels by up to 50%, IGF-I least.Animal · rat (not a human result)The Biochemical journal 1993, PMID 7683875
Not shown in any study we cite. Searches behind this page: PubMed search on 2 Oct 2026 for “("Long R3"[tiab] OR (LR3[tiab] AND (IGF[tiab] OR "IGF-1"[tiab] OR "IGF-I"[tiab] OR "insulin-like growth factor"[tiab])))”: 109 results. PubMed search on 2 Oct 2026 for “("Long R3 IGF-I"[tiab] OR "LR3 IGF-I"[tiab] OR "IGF-I LR3"[tiab] OR "LR3-IGF-I"[tiab] OR "IGF-1 LR3"[tiab] OR "LR3 IGF-1"[tiab] OR "[Long R3]IGF-I"[tiab]) AND (rat[tiab] OR rats[tiab] OR mice[tiab] OR infusion[tiab] OR muscle[tiab] OR pigs[tiab] OR in vivo[tiab])”: 38 results. PubMed search on 2 Oct 2026 for “"long R3 IGF"[tiab] OR "long-R3 IGF"[tiab] OR "LR3-IGF"[tiab] OR "LR3 IGF"[tiab] OR "R3 IGF-I"[tiab]”: 95 results. PubMed search on 2 Oct 2026 for “("LR3"[tiab] AND IGF[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab] OR clearance[tiab])”: 2 results.

Claim: it builds muscle

In streptozotocin-diabetic rats infused by pump, LR3-IGF-I and a truncated variant were 2.5 to 3 times more potent than IGF-I in restoring growth; this is rat data.[12]

In those diabetic rats all the peptides raised muscle protein-synthesis rates and RNA levels by up to 50%, IGF-I least of all.[12]

In rats carrying a mammary tumour, LR3-IGF-I had no positive effect on carcass protein and tumour growth rose, especially with LR3-IGF-I.[11]

In growing finisher pigs, a short LR3IGF-I infusion lowered daily gain and food intake rather than raising them.[8]

Claim: it raises growth hormone and IGF levels

In finisher pigs both IGF-I and LR3IGF-I suppressed plasma growth hormone, the opposite of a rise.[8]

In guinea pigs, LR3IGF-I raised the fractional weight of the adrenals, gut, kidneys and spleen, but overall growth was not stimulated.[9]

In artificially-reared neonatal pigs, LR3IGF-I increased daily weight gain in the second 9 days of one experiment (457 versus 386 g a day).[6]

Claim: it heals and protects other tissues

In rats, LR3IGF-I, but not IGF-I, increased body weight and the wet weight of the small and large intestine by 20%.[10]

In male 5XFAD Alzheimer's mice given intranasal LR3-IGF-1, body composition improved but cognition did not.[4]

In growth-restricted fetal sheep, a 1-week LR3 treatment did not improve growth.[3]

Claims with no human study behind them

A PubMed search of IGF-1 LR3 with muscle-mass and muscle-growth terms (2026-10-02) found 0 human-only papers and 6 under the animal filter; 0 carried a randomized-trial tag.

Calculated from pubmed query ("Long R3"[tiab] OR (LR3[tiab] AND (IGF[tiab] OR "IGF-1"[tiab] OR "IGF-I"[tiab] OR "insulin-like growth factor"[tiab]))) AND ("muscle mass"[tiab] OR "lean mass"[tiab] OR "lean body mass"[tiab] OR "fat-free mass"[tiab] OR "muscle growth"[tiab] OR "muscle hypertrophy"[tiab] OR "muscle protein synthesis"[tiab] OR "muscle strength"[tiab] OR sarcopeni*[tiab] OR "muscle wasting"[tiab] OR "muscle atrophy"[tiab]); date 2026-10-02; human only count 0; animal filter count 6; randomized filter count 0. Formula: counts as recorded in the goals.json ledger (PubMed [tiab] query with the human-only, animal and RCT filters shown)

A PubMed search of IGF-1 LR3 with bodybuilding and resistance-training terms (2026-10-02) found 0 human-only papers and 4 under the animal filter; 0 carried a randomized-trial tag.

Calculated from pubmed query ("Long R3"[tiab] OR (LR3[tiab] AND (IGF[tiab] OR "IGF-1"[tiab] OR "IGF-I"[tiab] OR "insulin-like growth factor"[tiab]))) AND (bodybuild*[tiab] OR "resistance training"[tiab] OR "resistance exercise"[tiab] OR "strength training"[tiab] OR "weight training"[tiab] OR weightlift*[tiab] OR "muscle hypertrophy"[tiab] OR "muscle mass"[tiab] OR "lean mass"[tiab] OR "anabolic steroid"[tiab] OR "anabolic steroids"[tiab] OR "anabolic-androgenic"[tiab]); date 2026-10-02; human only count 0; animal filter count 4; randomized filter count 0. Formula: counts as recorded in the goals.json ledger (PubMed [tiab] query with the human-only, animal and RCT filters shown)

A narrative review of performance-enhancing peptides notes the absence of regulatory approval for physique- or performance-related indications, so the muscle and bodybuilding claims above rest on animal work and on forum use.

Calculated from source PMID 42395176 abstract; human trials found 0. Formula: summary of the review abstract and the two ledger counts

Common questions

Is IGF-1 LR3 proven to work?

The strongest study we summarise for IGF-1 LR3 is human observational evidence, among 12 studies. That is not proof it works in people.

What does IGF-1 LR3 do?

In animal studies, IGF-1 LR3 is a long-arginine IGF-1 analogue with low affinity for IGF-binding proteins and high affinity for the IGF-1 receptor.[3]

Are there benefits of IGF-1 LR3 in people?

The cached abstracts are all animal or cell studies, and a narrative review lists IGF-1 LR3 among unapproved performance-enhancing peptides.[2]

More on IGF-1 LR3

Sources

  1. 1Detection of His-tagged Long-R³-IGF-I in a black market product.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2010PMID 20675162Accessed 2 Oct 2026
  2. 2The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026
  3. 3IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.American journal of physiology. Endocrinology and metabolism · 2025PMID 39679943Accessed 2 Oct 2026
  4. 4Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.Journal of Alzheimer's disease : JAD · 2025PMID 39610283Accessed 2 Oct 2026
  5. 5Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets.Journal of developmental origins of health and disease · 2023PMID 37114757Accessed 2 Oct 2026
  6. 6Insulin-like growth factor-I and analogues increase growth in artificially-reared neonatal pigs.The British journal of nutrition · 2002PMID 12067429Accessed 2 Oct 2026
  7. 7Clearance of IGFs and insulin from wounds: effect of IGF-binding protein interactions.The American journal of physiology · 1999PMID 10198302Accessed 2 Oct 2026
  8. 8Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs.The Journal of endocrinology · 1997PMID 9488001Accessed 2 Oct 2026
  9. 9Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig.The Journal of endocrinology · 1995PMID 7561636Accessed 2 Oct 2026
  10. 10Administration of insulin-like growth factor-I (IGF-I) peptides for three days stimulates proliferation of the small intestinal epithelium in rats.Gut · 1995PMID 8549937Accessed 2 Oct 2026
  11. 11Effects of insulin and insulin-like growth factors on protein and energy metabolism in tumour-bearing rats.The Biochemical journal · 1994PMID 8053901Accessed 2 Oct 2026
  12. 12Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects.The Biochemical journal · 1993PMID 7683875Accessed 2 Oct 2026
  13. 13PubMed search: ("Long R3"[tiab] OR (LR3[tiab] AND (IGF[tiab] OR "IGF-1"[tiab] OR "IGF-I"[tiab] OR "insulin-like growth factor"[tiab]))) (109 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14PubMed search: ("Long R3 IGF-I"[tiab] OR "LR3 IGF-I"[tiab] OR "IGF-I LR3"[tiab] OR "LR3-IGF-I"[tiab] OR "IGF-1 LR3"[tiab] OR "LR3 IGF-1"[tiab] OR "[Long R3]IGF-I"[tiab]) AND (rat[tiab] OR rats[tiab] OR mice[tiab] OR infusion[tiab] OR muscle[tiab] OR pigs[tiab] OR in vivo[tiab]) (38 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15PubMed search: "long R3 IGF"[tiab] OR "long-R3 IGF"[tiab] OR "LR3-IGF"[tiab] OR "LR3 IGF"[tiab] OR "R3 IGF-I"[tiab] (95 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  16. 16PubMed search: ("LR3"[tiab] AND IGF[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab] OR clearance[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  17. 17PubMed search: ("Long R3"[tiab] OR "IGF-1 LR3"[tiab] OR "LR3 IGF"[tiab] OR "LR3-IGF"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026

Found an error? Report a correction.